Germline alterations in DNA repair genes are implicated in cancer predisposition and can result in characteristic mutational signatures. However, specific mutational signatures associated with base excision repair (BER) defects remain to be characterized. Here, by analysing a series of colorectal cancers (CRCs) using exome sequencing, we identified a particular spectrum of somatic mutations characterized by an enrichment of C > A transversions in NpCpA or NpCpT contexts in three tumours from a MUTYH-associated polyposis (MAP) patient and in two cases harbouring pathogenic germline MUTYH mutations. In two series of adrenocortical carcinomas (ACCs), we identified four tumours with a similar signature also presenting germline MUTYH mutations. Taken together, these findings demonstrate that MUTYH inactivation results in a particular mutational signature, which may serve as a useful marker of BER-related genomic instability in new cancer types.
Introduction
Inherited genetic defects affecting several DNA repair pathways have been associated with cancer predisposition. Defects in mismatch repair (mainly MLH1, MSH2 or MSH6 mutations associated with hereditary non-polyposis colorectal cancer), base excision repair [MUTYH mutations in MUTYH-associated polyposis (MAP)], nucleotide excision repair (xeroderma pigmentosum genes in skin cancer), homologous repair (mainly BRCA1/2 in breast and other cancers), and the Fanconi anaemia pathway (FANC genes in acute myeloid leukaemia and squamous cell carcinomas) lead to different types of genetic instability that should be recognizable as distinct mutational signatures in cancer genomes [1] . At present, at least 30 mutational signatures have been identified by examining the cancers of more than 12 000 patients across 40 distinct human cancer types [2] [3] [4] and these are reported in the COSMIC database. Specific signatures have been related to BRCA1/2 mutaMutational signature associated with MUTYH deficiency in cancers 11 MUTYH is a DNA glycosylase involved in the repair of oxidative DNA damage, in particular of 8-oxoG, playing a critical role in the base excision repair (BER) pathway. Germline biallelic loss-of-function mutations in the MUTYH gene cause a condition predisposing to familial colorectal cancer (CRC) termed MUTYH association polyposis (MAP). Targeted and whole-exome sequencing (WES) studies revealed an excess of C > A mutations in MAP tumours [6, 7] . Here, we describe a strong association between a particular spectrum of C > A single base substitutions, similar to the previously reported signature 18 in the COSMIC database, and MUTYH mutations in a series of CRCs and in two series of adrenocortical carcinomas (ACCs) analysed by WES.
Materials and methods
We performed whole-exome sequencing from fresh frozen tumour samples from 37 patients with advanced CRC (stage 4, treated with anti-EGFR antibodies), and two adenomas (P1 and P2) and a carcinoma (TU) from one patient with MAP (supplementary material, Table  S1 ). Analysis of the triple knockout mouse model [8] and the ACC cohorts [9, 10] were based on the mutation lists provided in the original publications. We used the Wellcome Trust Sanger Institute mutational signatures framework [2] to extract signatures from the catalogues of somatic mutations identified in CRC and ACC samples. Detailed methods are presented in supplementary material, Supplementary materials and methods.
Results and discussion
We performed a de novo analysis of the mutational spectrum of 37 CRCs using the Wellcome Trust Sanger Institute (WTSI) mutational signatures framework [2] . Mutational signature analysis identified three distinct signatures closely related to the previously described signatures 1, 5, and 18 [3] (supplementary material, Figure S1A ). As previously reported [11] , the clock-like signature 1 (but not signature 5) was positively correlated with age (Pearson coefficient = 0.2, p = 0.0042; supplementary material, Figure S1B ). In contrast, the aetiology of signature 18 remains unknown. Signature 18, characterized by an enrichment of C > A transversions in NpCpA or NpCpT contexts ( Figure 1A ), has been described in neuroblastoma and in incidental samples of other cancer types, such as ACC, breast, and stomach carcinomas [11] , but not in CRC. In our series, signature 18 was the dominant signature in two samples (CRC103 and CRC355, Figure 1B , C). Strikingly, these two cases were the only cases harbouring germline mutations (i.e. germline variants with a reported frequency ≤ 1% in the ExAC database [12] ) in the MUTYH gene (p = 0.0015, Fisher's exact test). CRC103 displayed a nonsense mutation (rs762307622, W156*, ExAC frequency in non-Finnish Europeans = 0%) potentially leading to a truncated protein lacking most functional domains (supplementary material, Table  S2 ). CRC355 harboured the known pathogenic variant rs36053993 (ExAC frequency = 0.4%) leading to the amino acid substitution G396D [13] . These two variants were heterozygous in the normal samples but became homozygous in the two tumours following loss of the wild-type allele ( Figure 1D ). To confirm the link between signature 18 and MUTYH mutations, we analysed by WES two adenomas (P1 and P2) and a carcinoma (TU) from one patient with MAP harbouring two different missense mutations of MUTYH: a Y179C mutation (rs34612342, ExAC frequency = 0.25%) known to be associated with polyposis [14] , and an R495P mutation (ExAC frequency = 0%) predicted to be possibly damaging by using SNP&Go and SIFT software (supplementary material, Table S2 ). Signature 18 was the dominant signature in these three samples, accounting for more than 70% of mutations ( Figure 1B) . As a result, the mutational spectrum in MUTYH-mutated cases displayed a dramatic increase of C > A mutations at trinucleotide contexts characteristic of signature 18 ( Figure 1C ). The somatic mutations identified by Rashid et al in eight colorectal adenomas from two MAP patients [6] also displayed a trinucleotide spectrum very similar to signature 18 (cosine similarity = 0.85; supplementary material, Figure S2 ). KRAS G12C mutations are particularly frequent in MAP-related colorectal tumours [15] and were observed in our three MAP samples. These mutations result from C > A substitutions occurring in a CCA trinucleotide context showing a high mutation probability in signature 18 ( Figure 1A) . Thus, BER deficiency makes MUTYH-mutated colorectal cells particularly prone to acquiring C > A mutations at CCA sites, explaining the high frequency of KRAS G12C mutations in these patients.
To investigate further the link between MUTYH deficiency and the mutational signature 18, we analysed the mutations reported by Ohno et al in an Mth1/Ogg1/Mutyh triple knockout mouse model (TOY-KO), which accumulates 8-oxoG in the nuclear DNA of gonadal cells [8] . Using WES, Ohno et al identified 262 germline mutations acquired by the offspring of these mice. The trinucleotide mutation pattern of these mutations was highly consistent with the mutational pattern observed in our MUTYH-mutated CRC cases (Figure 2A) , and a hierarchical clustering with the 30 signatures described in COSMIC showed that the TOY-KO mutational signature clustered together with signature 18 ( Figure 2B) . Indeed, the trinucleotide context frequencies of TOY-KO mice mutations and signature 18 displayed a cosine similarity of 0.94, where a similarity of 1.00 reflects a perfect match ( Figure 2C) .
In a recent study, we analysed the whole-exome sequences of 45 ACCs and reported two ACCs with a hypermutator phenotype dominated by C > A transversions [9] . Mutational signature analysis of these 45 Figure 3A , B). These two tumours were the only ones in the cohort harbouring germline MUTYH mutations (p = 0.0010, Fisher's exact test): ACC33 harboured the missense G396D variant (rs36053993), whereas ACC39 harboured the R241W variant (rs34126013, ExAC frequency = 0.005%) (supplementary material, Table S2 ). These two MUTYH mutations are also known to be pathogenic [13, 16] and were found in cancers with deletion of the wild-type allele by LOH of chromosome 1 ( Figure 3C ). In an independent series of 91 ACCs from the TCGA [10] , we identified two tumours with signatures similar to signature 18 (supplementary material, Figure S3 ). Both tumours displayed rare pathogenic MUTYH mutations (Y179C and W156*; supplementary material, Table  S2 ), with loss of the wild-type allele in the tumour (supplementary material, Figure S3 ), versus none of the 89 other samples (p = 0.00024, Fisher's exact test).
To confirm the similarity of signatures related to MUTYH mutations in different biological contexts, we then performed an unsupervised classification of the mutational profiles observed in CRC and ACC cases, together with the 30 signatures currently described in COSMIC and the mutational signature of the TOY-KO mouse model. The hierarchical clustering (cosine distance, Ward method) revealed a MUTYH cluster comprising the three MAP tumours from our series, the two MAP patients from Rashid et al [6] , CRC103, ACC33, and ACC39, together with the signature of TOY-KO mice mutations and COSMIC signature 18 ( Figure 4) . One MUTYH-mutated CRC (CRC355) clustered separately, due to the high prevalence of signature 1 in addition to signature 18 in this sample.
Taken together, our data suggest that mutational signature 18 reflects the accumulation of C > A mutations after incorrect replication of 8-oxoG. These mutations may accumulate in the context of defective base excision repair, e.g. in MUTYH-deficient cancers, or potentially by excessive generation of reactive oxygen species (ROS). Signature 18 has also been described in breast, stomach cancer, and neuroblastoma. We examined the whole-genome sequences of 560 breast cancers [17] , 478 stomach cancers (TCGA-STAD), and 56 neuroblastomas [18] , but we did not find any association between signature 18 and MUTYH mutations in these cancer types. Increased generation of ROS or other genetic defects or epigenetic alterations of BER pathway genes may explain signature 18 in these cancer types. Consistently, signature 18 is highly prevalent in neuroblastoma, a cancer type in which reactive oxygen species are known biological stimuli [19] . Finally, this study shows that mutational signatures can be used to detect DNA damage defects in tumours, even before a causal mutation is identified. This approach led us to identify, for the first time to our knowledge, pathogenic MUTYH mutations in ACC patients. This finding has potential clinical utility since these patients may benefit from genetic counselling and treatments (e.g. immunotherapy) taking advantage of their high mutation load. Mutational signatures are thus a useful tool that may be used in the clinics to identify patients who may benefit from specific therapies [20] . Figure S1 . Mutational signatures and correlations for 38 CRC patients 
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